Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea

Clicks: 2
ID: 319532
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #145 of 151 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: To review the efficacy and safety of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea (uUGG). SUMMARY: A literature search was performed using PubMed and Google Scholar with the search terms "zoliflodacin," "AZD0914," and "ETX0914." All relevant English-language articles of studies assessing the efficacy and safety of zoliflodacin for the treatment of uUGG were included. Other resources included abstracts presented at recent conferences, the manufacturer's website, and prescribing information. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic with a novel mechanism of action and has been shown to be highly active against Neisseria gonorrhoeae, including strains resistant to other antibiotics such as ceftriaxone and azithromycin. It is FDA approved for the treatment of uUGG in adult and pediatric patients aged 12 or older and weighing at least 35 kg and is administered as a one-time oral dose of 3,000 mg. In a large phase 3 trial, zoliflodacin was noninferior to ceftriaxone plus azithromycin for the treatment of uUGG in both men and women and demonstrated a favorable safety and tolerability profile. CONCLUSION: Zoliflodacin is a newly approved antibiotic with a novel mechanism of action that is highly effective for the treatment of uUGG. It is given as a single dose that can be administered orally at the time of diagnosis, thereby avoiding the intramuscular injection necessary with ceftriaxone. It is also effective against gonorrhea strains resistant to other antibiotics.
Reference Key
openalex_W7167204039 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Spencer H. Durham, Elias B. Chahine
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag204
URL
https://doi.org/10.1093/ajhp/zxag204
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.